ArticleOphthalmology science
Integration of Immunometabolic Composite Indices and Machine Learning for Diabetic Retinopathy Risk Stratification: Insights from NHANES 2011 - 2020.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antioxidant vitamin index and risk of age-related macular degeneration: multicenter validation and clinical translation.npj aging · 2026Article
- A clinically interpretable machine learning model for early detection of diabetic retinopathy in multiple community health centers.Frontiers in endocrinology · 2026Article
- Decoding the Bone-Eye Axis: Machine Learning for Age-Related Macular Degeneration Risk Prediction.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Targeting the NEK7/NLRP3 Inflammasome Axis: Synergistic Protection of Intravitreal MCC950 and Systemic Metformin Against Diabetic Retinopathy in Rats.Endocrinology, diabetes & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between immunometabolic composite indices and diabetic retinopathy (DR) and to develop predictive models using machine learning (ML) techniques to improve early detection and risk stratification for DR. Design: A cross-sectional study. Subjects and Controls: Data from the National Health and Nutrition Examination Survey 2011-2020 were analyzed, involving 8249 participants categorized into healthy controls (n = 6830), diabetes without retinopathy (n = 918), and DR (n = 501). Methods: Immunometabolic indices reflecting insulin resistance, inflammation, and lipid metabolism were evaluated. Multivariate logistic regression models assessed associations with DR, and Bayesian kernel machine regression analyzed nonlinear interactions. Eight ML models, including ensemble methods, were developed to predict DR risk, with feature importance determined by SHapley Additive exPlanations. Main Outcome Measures: The primary outcome was DR status, classified according to the ETDRS criteria from fundus photography. Results: Key immunometabolic indices, notably Frailty Index (FRAILTY) and fasting serum insulin (FSI), were significantly associated with increased DR risk, whereas the metabolic score for insulin resistance (METS) showed a protective effect. Bayesian kernel machine regression highlighted complex interactions among indices. Machine learning models achieved high predictive accuracy, particularly XGBoost and LightGBM (area under the curve > 0.9). SHapley Additive exPlanations analyses identified FRAILTY, FSI, and METS as the most influential predictors. Conclusions: Immunometabolic dysregulation significantly contributes to DR progression beyond traditional risk factors such as hyperglycemia alone. Incorporating immunometabolic indices into predictive models substantially enhances DR risk stratification, facilitating personalized screening and intervention strategies. Machine learning approaches effectively identify high-risk individuals, underscoring their utility in clinical practice for early DR detection and targeted preventive care. Financial Disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.